Pharmaceuticals News

Le chiffre d'affaires du premier trimestre 2026 a atteint 384 M€ : +7,7 % à taux de change et périmètre constants par rapport au T1 2025.+2,2 % à taux réels, impactés par des effets de change...

First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025+2.2% at actual rates impacted by significant currency headwinds Balanced growth in both segments...

COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual...

Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership

NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC...

Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting.

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company...

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc....